Patients with advanced clear cell RCC whose disease progressed after 1-3 prior systemic therapies (including an anti–PD- [L]1 therapy) were randomly assigned 1:1 to belzutifan 200 mg or 120 mg daily: ...
A team has identified a previously unknown phase of the immune response. The results challenge long-standing assumptions about the process called 'T-cell priming'. These new insights have significant ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results